PriceTargets.com logo

TCR2 Therapeutics - TCRR Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.48 As of 06/1/2023 09:00 PM ET
▼ -0.09 (-5.73%)
Get New TCR2 Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCRR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCRR

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for TCR2 Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.48.

This chart shows the closing price for TCRR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in TCR2 Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/24/2023MizuhoDowngradeBuy ➝ Neutral$20.00 ➝ $1.72Low
3/23/2023WedbushReiterated RatingNeutral$2.18 ➝ $1.68Low
3/23/2023EF Hutton Acquisition Co. IReiterated RatingHold$2.00Low
3/9/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$18.00 ➝ $3.00Low
3/7/2023Truist FinancialDowngradeBuy ➝ Hold$8.00 ➝ $3.00Low
3/7/2023HC WainwrightDowngradeBuy ➝ NeutralLow
1/5/2023Piper SandlerBoost TargetOverweight$8.00 ➝ $10.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageHold$2.00Low
11/21/2022HC WainwrightLower TargetBuy$14.00 ➝ $13.00Low
11/8/2022Piper SandlerLower Target$16.00 ➝ $8.00Low
8/23/2022Truist FinancialLower Target$18.00Low
8/8/2022Roth CapitalReiterated RatingBuyLow
5/19/2022HC WainwrightLower TargetBuy$19.00 ➝ $14.00Low
5/12/2022Piper SandlerLower Target$23.00 ➝ $15.00Low
3/22/2022Piper SandlerLower Target$26.00 ➝ $23.00Low
1/19/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$28.00 ➝ $5.00High
1/13/2022HC WainwrightLower TargetBuy$25.00 ➝ $19.00High
11/10/2021SVB LeerinkLower TargetMarket Perform$8.00 ➝ $7.00High
10/21/2021BMO Capital MarketsLower TargetOutperform$44.00 ➝ $38.00Low
10/21/2021MizuhoLower TargetBuy$51.00 ➝ $20.00High
10/20/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$18.00 ➝ $8.00High
9/20/2021Truist FinancialLower TargetBuy$40.00 ➝ $29.00High
9/20/2021HC WainwrightReiterated RatingBuy$37.00 ➝ $25.00High
9/17/2021WedbushDowngradeOutperform ➝ Neutral$45.00 ➝ $11.00High
8/20/2021HC WainwrightReiterated RatingBuy$37.00Medium
8/6/2021SVB LeerinkLower TargetOutperform$34.00 ➝ $31.00High
8/6/2021BMO Capital MarketsLower TargetOutperform$53.00 ➝ $44.00High
8/5/2021Roth CapitalReiterated RatingBuyHigh
6/24/2021The Goldman Sachs GroupInitiated CoverageBuy$30.00High
5/14/2021WedbushLower TargetOutperform$57.00 ➝ $45.00High
5/13/2021MizuhoInitiated CoverageBuy$51.00High
4/11/2021MizuhoReiterated RatingBuy$51.00High
3/12/2021MizuhoLower TargetBuy$58.00 ➝ $51.00Medium
3/11/2021BMO Capital MarketsLower TargetOutperform$65.00 ➝ $56.00Low
3/11/2021Piper SandlerBoost TargetOverweight$45.00 ➝ $55.00Medium
3/11/2021SVB LeerinkLower TargetOutperform$41.00 ➝ $34.00Low
12/14/2020Piper SandlerBoost TargetOverweight$35.00 ➝ $45.00High
12/14/2020BMO Capital MarketsBoost Target$46.00 ➝ $65.00Low
12/14/2020HC WainwrightBoost TargetBuy$32.00 ➝ $37.00High
12/13/2020MizuhoReiterated RatingBuy$33.00High
11/30/2020Roth CapitalBoost TargetBuy$35.00 ➝ $38.00Low
8/20/2020MizuhoInitiated CoverageBuyMedium
8/13/2020HC WainwrightLower TargetBuy$33.00 ➝ $32.00High
8/12/2020Truist FinancialInitiated CoverageBuyHigh
8/12/2020SVB LeerinkLower TargetOutperform$26.00 ➝ $25.00High
8/12/2020Piper SandlerInitiated CoverageOverweight$35.00Low
7/27/2020HC WainwrightBoost TargetBuy$19.00 ➝ $33.00High
7/27/2020Roth CapitalUpgradeNeutral ➝ Buy$16.00 ➝ $35.00High
7/27/2020WedbushBoost TargetOutperform$25.00 ➝ $32.00High
6/23/2020HC WainwrightReiterated RatingBuy$19.00High
5/18/2020HC WainwrightReiterated RatingBuy$19.00High
3/31/2020HC WainwrightReiterated RatingBuyHigh
3/30/2020WedbushReiterated RatingOutperformHigh
3/30/2020SVB LeerinkReiterated RatingOutperformHigh
12/11/2019HC WainwrightReiterated RatingBuy$19.00Medium
11/13/2019HC WainwrightReiterated RatingBuy$19.00High
11/4/2019HC WainwrightInitiated CoverageBuy$19.00Medium
5/31/2019Roth CapitalInitiated CoverageNeutral$16.00High
(Data available from 4/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
TCR2 Therapeutics logo
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $1.48
Low: $1.48
High: $1.63

50 Day Range

MA: $1.65
Low: $1.48
High: $1.98

52 Week Range

Now: $1.48
Low: $0.82
High: $3.88

Volume

3,913,300 shs

Average Volume

494,777 shs

Market Capitalization

$58.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

Frequently Asked Questions

What sell-side analysts currently cover shares of TCR2 Therapeutics?

The following Wall Street sell-side analysts have issued research reports on TCR2 Therapeutics in the last twelve months:
View the latest analyst ratings for TCRR.

What is the current price target for TCR2 Therapeutics?

0 Wall Street analysts have set twelve-month price targets for TCR2 Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for TCR2 Therapeutics in the next year.
View the latest price targets for TCRR.

What is the current consensus analyst rating for TCR2 Therapeutics?

TCR2 Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TCRR.

What other companies compete with TCR2 Therapeutics?

Other companies that are similar to TCR2 Therapeutics include LENZ Therapeutics, JATT Acquisition, AVROBIO, Aligos Therapeutics and Entera Bio. Learn More about companies similar to TCR2 Therapeutics.

How do I contact TCR2 Therapeutics' investor relations team?

TCR2 Therapeutics' physical mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company's listed phone number is (617) 949-5200 and its investor relations email address is [email protected]. The official website for TCR2 Therapeutics is www.tcr2.com. Learn More about contacing TCR2 Therapeutics investor relations.